1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Corbus Seeking Way Forward In Systemic Sclerosis After Phase III

Results For Placebo On Par With High-Dose Lenabasum

 
• By Mandy Jackson

The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations. 

Dominoes
Lenabasum hit a roadblock in systemic sclerosis where results were similar to placebo • Source: Shutterstock

Corbus Pharmaceuticals Holdings, Inc.’s cannabinoid receptor type 2 (CB2) agonist lenabasum – the company’s only clinical-stage drug candidate – failed its first pivotal trial test, but the company is reviewing the data in hopes of finding a way forward for the drug in systemic sclerosis. Corbus said on 8 September that the similar results in the lenabasum and placebo arms of the Phase III clinical trial were due to background immunosuppressive therapy.

The Norwood, MA-based company reported top-line results on 8 September from the RESOLVE-1 trial and said its ongoing analysis of the best use for lenabasum in systemic sclerosis may require confirmation in another study

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.